|
Market Closed -
Nasdaq
21:00:00 13/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 2.540 USD | -0.39% |
|
-10.88% | +55.83% |
| 11-10 | Ovid Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| 10-06 | Guggenheim Initiates Ovid Therapeutics at Buy | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 479M | - | - | - | ||
| 66.33B | |||||
| 60.62B | |||||
| 55.5B | |||||
| 47.58B | |||||
| 43.69B |
Select your edition
All financial news and data tailored to specific country editions
